In addition, a combination treatment using a TrxR inhibitor ([Au(d2pype)2]Cl) and a BTK inhibitor (ibrutinib) could synergistically lead to DLBCL cell death, suggesting that co-targeting the Trx system and the BCR signalling pathway by inhibiting TrxR and BTK activity may be a novel therapeutic approach to explore further with respect to DLBCL treatment. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.